|
Genetic Engineering & Biotechnology News
Stem Cell Research in the EU and U.S.
Philippa Montgomerie , Grant Strachan , Aaron Fountain, J.D. , and Lisa A. Haile, J.D., Ph.D.
On October 18, 2011, the Court of Justice of the European Union (CJEU) ruled that processes that involve the derivation of stem cells from a human embryo at the blastocyst stage, entailing the destruction of that embryo, could not be patented. This article presents a brief synopsis of the CJEU decision and compares the current differences in the patentability of stem cells in Europe and the U.S. Full Article
Genetic Engineering & Biotechnology News
Where Does Geron’s Exit from Embryonic Stem Cells Leave the Field?
Patricia F. Dimond, Ph.D.
Geron has halted its stem cell therapeutics programs. Waiting for the potential payoff proved too far off for the firm; it would have spent $25 million per year to continue. Investors seem to be sitting the space out, and any company that lands Geron’s technology must have not just the money but also the will to further hESC-based therapeutic programs. Full Article
Genetic Engineering & Biotechnology News
U.S. Stem Cell Firms Partnering Overseas
Alex Philippidis
American companies focused on stem cell treatments and technology platforms have met with success in finding partnerships and revenues overseas in the past decade. The two main factors that explain this trend are: the attractiveness of Asian markets in terms of population as well as willingness by national governments to invest plus Asia’s lower regulatory hurdles. Full Article
Genetic Engineering & Biotechnology News
Demand Escalates for iPSC Life Science Tools
Lisa Carey and Michael Tapella
Since the introduction of induced pluripotent stem cell (iPSC) techniques in 2006, researchers have successfully created both iPSC-derived healthy state and disease-specific cell lines that have potential to replace current tools used in toxicity and drug efficacy screening. Within only a few years, a number of commercial opportunities have risen all along the iPSC value chain. Full Article
Antioxidants & Redox Signaling
Epigenetic Landscape of Pluripotent Stem Cells
Ji Woong Han and Young-sup Yoon
Exploration of the mechanisms governing pluripotency in embryonic stem cells is important for understanding reprogramming mechanisms and stem cell behavior of these cells. This review focuses on changes in epigenetic marks during reprogramming and their role in cell fate. Full Article
Tissue Engineering Part B: Reviews
Progress in the Tissue Engineering and Stem Cell Industry
Ana Jaklenec, Andrea Stamp, Elizabeth Deweerd, Angela M Sherwin, and Robert S. Langer
This report shows that the tissue engineering and stem cell industry is on a path to success. It includes data through mid 2011, showing an almost threefold growth in commercial sales over the past four years. In addition, the number of companies selling products or offering services has grown over twofold to 106, and they are generating $3.5 billion in sales. Full Article
|
